Aarti Drugs Limited · NSE:AARTIDRUGS
Aarti Drugs — Q3 FY2021 Earnings Presentation
44 slides from Aarti Drugs's earnings presentation, Jan 28, 2021
Slide 1: Stock exchange cover letter for Q3FY21 results presentation
Ref: ADL/SE/2020-21 January 28, 2021 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE Limited National Stock Exchange of India Phiroze Jeejeebhoy Towers, Limited, Dalal Street, “Exchange Plaza”, Bandra - Kurla Mumbai – 400 001 Complex, Bandra (E), Mumbai – 400051 BSE CODE –
Slide 2: Investor Presentation December 2020
Investor Presentation December 2020
Slide 3: Safe Harbour Statement
Safe Harbour Statement This investor presentation has been prepared by Aarti Drugs Limited(“ADL”) and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplie
Slide 4: Table Of Contents
Company Overview …………………………………………………………………………..…..04 - 16 Table Of Contents Pharmaceutical Industry Overview & Growth Drivers …………………………..17 - 21 Investment Proposition & Outlook ………………………………………………………..22 - 24 R & D Product Pipeline ………………………………………………………………………….25 - 27 Result Summary ………………………………………
Slide 5: Company Overview
Company Overview
Slide 6: Company Overview
Company Overview Aarti Drugs Limited was established in the year 1984 and forms part of $1000 Million Aarti Group of Industries with robust R&D Division at Tarapur, Maharashtra Industrial Development Corporation (MIDC) in close vicinity to manufacturing locations. The Company is engaged in the manuf
Slide 7: Key facts and figures
Key facts and figures Largest producer of One of the leading producers 12 100+ 1,536 50+ Nimesulide in the world of Metformin in the world Manufacturing Countries Employees API Molecules facilities One of the Largest producer in Fluoroquinolones in the Largest producer of world Ketoconazole in the w
Slide 8: Milestones
Milestones 1984 1993 1996 1998 2003 2008 2011 2014 2015 2017 2019 Listed On BSE Limited Turnover of Approval of Turnover of Rs. 1000 Crore Rs. 100 Crores Turnover Rs. 100 Crores USFDA Plant Pinnacle Life Science Pvt. Ltd. 100% holdings in Pinnacle Life Science Pvt. Ltd. Incorporation Amalgamation of
Slide 9: Awards & Accolades
Awards & Accolades 1991-92 2001 2005-06 2009 2012 2013 CHEMEXCIL CHEMEXCIL AVAYA GLOBAL CONNECT PHARMEXCIL PHARMEXCIL ABBOTT Outstanding Performance in Outstanding Performance in Export Customer Responsiveness Outstanding Performance in Outstanding Performance in Best Vendor of the year Export Expor
Slide 10: Corporate Social Responsibility
Corporate Social Responsibility KOSBAD GIRL'S HOSTEL MURBE SMARAK AARTI DRUGS LIMITED | Investor Presentation | Dec 2020 9
Slide 11: Board Of Directors & Management
Board Of Directors & Management Mr. Prakash M. Patil Mr. Harshit M. Savla Mr. Harit P. Shah Mr. Rashesh C. Gogri Mr. Adhish P. Patil Chairman, MD & CEO Joint Managing Director Whole Time Director Managing Director Chief Financial Officer Shri Prakash M. Patil is Chairman, Managing Shri Harshit M. Sa
Slide 12: Business overview
Business overview Domestic market share leader in Export Clientele is well diversified with the topmost client most of its top 10 products contributing to only 3.45% of total export sales Local clientele is well diversified with the topmost client Top 10 Export clients contribute to only 19.64% of t
Slide 13: Revenue Split
Revenue Split Segment-wise Revenue Split Therapeutic wise Sales of the API Segment 1% YTD Dec’20 4% 3% YTD Dec’20 4% 4% 4% Anti-biotic API 7% 13% Anti-protozoals Formulation 44% Anti-inflamatory 10% Anti-diabetic Speciality Chemicals Anti-fungal Intermediates Cardioprotectant 13% Others Speciality 7
Slide 14: Plant Capacity
Plant Capacity Monthly API Capacity 3588 Mt/m Particulars 2019-20 2018-19 2017-18 Units Mt Mt Mt Installed 43,060 29,758 25,714 Production 32,753 22,495 19,261 Captive 7,162 4,690 3,925 Net Production 25,591 17,805 15,337 AARTI DRUGS LIMITED | Investor Presentation | Dec 2020 13
Slide 15: Overview of facilities
Overview of facilities 1. Pinnacle Life science Pvt Ltd. o Formulation Plant WHO-GMP 1. Aarti Drugs Ltd-Sarigam 2902-04 2. Aarti Drugs Ltd-Sarigam 211/213 o WHO-GMP o WHO-GMP / COFEPRIS / CEP 1. Aarti Drugs Ltd.E-22 3. Aarti Drugs Ltd.E-21 o Australian Government – o WHO-GMP 7. Aarti Drugs Ltd.E-120
Slide 16: Overview of facilities: global presence
Overview of facilities Global 1 Afghanistan 41 Iraq 81 Spain 2 Africa 42 Ireland 82 Sri Lanka 3 Algeria 43 Israel 83 Sudan 4 Argentina 44 Italy 84 Sultanate Of Oman 5 Armenia 45 Japan 85 Switzerland 46 Jordan 86 Syria Europe 6 Australia 13% 7 Bahamas 47 Kenya 87 Taiwan 8 Bangladesh 48 Korea 88 Tanza
Slide 17: Key local clientele
Key local clientele AARTI DRUGS LIMITED | Investor Presentation | Dec 2020 16
Slide 18: Pharmaceutical Industry Overview & Growth Drivers
Pharmaceutical Industry Overview & Growth Drivers
Slide 19: Pharmaceutical industry
Pharmaceutical industry Formulations Contract Research and Manufacturing Services (CRAMS) o Largest exporter of formulations in terms of volume, with 14 per o Fragmented market with more than 1,000 players cent market share and 12th in terms of export value. Drug formulation exports from India reach
Slide 20: Industry Going Forward
Industry Going Forward API IS THE LARGEST SEGMENT OF THE INDIAN PHARMACEUTICALS SECTOR Pharmaceutical Industry Manifold rise in public healthcare spending Increase in the size of middle class households Improvement in medical infrastructure US$ 33 Bn US$ 55 Bn Increase in the penetration of health i
Slide 21: Indian Pharmaceutical Industry
Indian Pharmaceutical Industry PHARMA EXPORT TO CONTINUE WITNESSING POSITIVE GROWTH Major Export Destinations in India’s Pharma Export in FY18 (%) o India, the third-largest pharmaceutical market in Asia, North America 15.30% o Supplies over 50 per cent of global demand for various vaccines, 40 per
Slide 22: Growth Drivers
Growth Drivers Pharma Vision 2020 by the government’s Department of India’s cost of production is approximately 33 per cent lower than Pharmaceuticals aims to make India a major hub for end-to-end that of the US. drug discovery Government has set aside an investment worth US$307.6 million (INR20 bil
Slide 23: Investment Proposition & Outlook
Investment Proposition & Outlook
Slide 24: Investment Proposition
Investment Proposition Around 75 to 100 cr CAPEX is STRONG PROCESS being done every year to Reliable in terms of IMPROVEMENT R&D, Newer capacities fuel growth for coming 5 years quality and timely COST LEADERSHIP, established since last GREEN FIELD considering higher gestation period deliveries. Hon
Slide 25: Outlook
227 Outlook ANTI DIABETIC: SPECIALITY CHEMICALS: o CEP approval in 2016 which opened up European markets o Incremental expansion of our multipurpose chloro-sulphonation line in existing block o Manufacturing over 1000 TPM making it one of the largest metformin player. o Greenfield expansion in near
Slide 26: R & D and Product Pipeline
R & D and Product Pipeline
Slide 27: Research & Development Focus
Research & Development Focus Manufacturing facilities at Tarapur and Sarigam are supported by R&D section located at Tarapur, where focus is mainly on API process developments. R&D Center located at Turbhe, Mumbai is for development of complex Oral Solids for Regulated markets as well as Emerging wo
Slide 28: API Product Pipeline
API Product Pipeline Product Under Development Product Under Pipeline Sr. No. Therapeutic Category Products Sr. No. Therapeutic Category Products 1 Alcoholism Treatment Acamprosate 1 Antidiabetic Vildagliptin 2 Anticoagulant Dabigatran 2 Antidiabetic Teneligliptin 1 Anti Cholesterol Atorvastatin 3 A
Slide 29: Finished Dosage: Products Under Development
Finished Dosage : Products Under Development Product Under Development : New Age Molecules For regulated Markets Sr. No.` Therapeutic Category Products Strength 1 Anti-Coagulant Rivaroxaban Tablets 2.5/10/15/20 mg 2 Anti-Coagulant Apixaban Tablets 2.5mg & 5mg 3 Anti-Coagulant Dabigatran Tablets 75/1
Slide 30: Finished Dosages: New Age Molecules and LATAM Products
Finished Dosages: Product Under Development : New Age Molecules Product Under Development: LATAM & Emerging Markets Sr. Therapeutic Category Products Strength No.` 1 Anti-Diabetic Metformin Tablet 850mg 2 Anti-Protozol Metronidazole Tablet 500mg 3 Anti-Diabetic Metformin Prolonged release Tablet 500
Slide 31: Finished Dosages: Product Pipeline
Finished Dosages: PRODUCT PIPELINE Product Under Pipeline Sr.No.` Therapeutic Category Products Strength 1 Anti-Platelet Ticagrelor Tablets 60/90mg 2 Anticonvulsants Pregabalin Capsule 75mg & 150mg 3 Antiretroviral 600 + 300mg Abacavir +Lamivudine tablets Antiretroviral 4 300mg Atazanavir tablets 30
Slide 32: Result Summary
Result Summary —
Slide 33: Results Summary – Consolidated Q3FY21 and FY20
Results Summary – Consolidated Q3FY21 and FY20 (in ₹ Million) Particulars Q2 FY21 Q1 FY21 Q2 FY20 Y-o-Y (%) FY 20 FY 19 Y-o-Y (%) Revenue from Operations 5,303 5,781 4,735 11.98% 18,061 15,609 15.71% Other Income 20 2.9 2 15 24 Total Income 5,323 5,784 4,738 12.35% 18,076 15,633 15.62% Cost of Mater
Slide 34: Revenue Split – Consolidated Q3FY21
Revenue Split – Consolidated Q3FY21 Revenue EBITDA PAT 5,303 1,078 680 677 4,735 278 Q3 FY20 Q3 FY21 Q3 FY20 Q3 FY21 Q3 FY20 Q3 FY21 API Formulation Specialty Chemicals Intermediate & Others Q3FY21 4213 707 171 212 Q3FY20 3635 671 143 286 Note: 1.. On Consolidated Basis 2. Revenue excluding Other In
Slide 35: Results Summary – FY20
Results Summary – FY20 Revenue EBITDA PAT 18,061 2,678 1414 2,135 898 15,609 FY 19 FY 20 FY 19 FY 20 FY 19 FY 20 API Formulation Specialty Chemicals Intermediate & Others FY20 14,414 2,084 566 997 FY19 13,086 1,498 434 591 Note: On Consolidated Basis Number In ₹ Million EBITDA is including other inc
Slide 36: Financial Overview
Financial Overview
Slide 37: Robust Financial Performance
Robust Financial Performance Revenue EBITDA & EBITDA Margin CAGR-12.22% CAGR-11.11% 16.03% 15.92% 16.50% 2,600 15.41% 16.00% 15.50% 2,100 15.00% 1,600 14.81% 14.50% 14.00% 1,100 13.63% 13.50% 13.00% 600 11,398 11,992 12,447 15,634 18,076 1,757 1,909 1,995 2,135 2,678 12.50% 100 12.00% FY 16 FY 17 FY
Slide 38: Robust Financial Performance
Robust Financial Performance Earning Per Share (in ₹) Gearing Ratio (x) 1.36 60.57 1.15 1.19 0.93 38.48 33.46 34.41 28.38 0.58 FY16 FY17 FY18 FY19 FY20 FY16 FY17 FY18 FY19 FY20 Net Worth (in ₹ million) RoE(%) & RoCE (%) RoE RoCE 6,525 23.69% 5,435 19.82% 20.44% 18.07% 17.97% 4,554 4,001 20.60% 3,467
Slide 39: Profit & Loss Statement
Profit & Loss Statement (in ₹ Million) Particulars 2020 2019 2018 2017 2016 Revenue from operations (gross) 18,061 15,609 12,626 12,881 12,283 Less : Excise duty - - -189 -929 -934 Revenue from operations (net) 18,061 15,609 12,436 11,952 11,349 Other Income 15 24 11 40 50 Total Revenue 18,076 15,63
Slide 40: Balance Sheet
Balance Sheet Particulars 2020 2019 2018 2017 2016 Share Capital 233.00 235.82 235.82 238.57 (in ₹ Million) 242.17 Other Equity 6,291.89 5,198.64 4,318.46 3,762.75 3,224.45 Total Equity Attributable to Equity Holders of the Company 6,524.89 5,434.46 4,554.28 4,001.32 3,466.62 Non- Controlling Intere
Slide 41: Cash Flow Statement
Cash Flow Statement (in ₹ Million) Particulars 2020 2019 2018 2017 2016 A Cash Flow from Operating Activities Net Profit before Tax and Extraordinary items 1,852.88 1,310.23 1,245.03 1,160.12 952.75 ADJUSTMENT FOR: Depreciation & Amortisation 487.53 425.62 400.63 384.63 365.28 Provision for Bad & do
Slide 42: Shareholder Information
Shareholder Information
Slide 43: Shareholder Information
Shareholder Information Stock Data (As on 31st December 2020) Market Capitalization (₹) Shares Outstanding Free Float Symbol (NSE/ BSE) 65,720 mn 93.20 mn 39.80% AARTIDRUGS / 524348 Stock Performance Chart (As on 31st March 2020) Ownership Summary Base = 100 ADRG.NS NIPHARM 4.73 35.07 Source: Factse
Slide 44: Thank You
Thank You Aarti Drugs Ltd Mahendra Inds. Estate, Ground Floor, Plot No. 109‐D Road No. 29, Sion (E), Mumbai‐400 022 (India) Tel: +91 22 24019025 / 24072249 Fax: +91 22 24073462 / 24070144 E‐mail: investorrelations@aartidrugs.com